Viyash Scientific Acquires Italy’s BioForLife for Approximately ₹188 Crore 

Key Highlights: 

• Viyash Scientific, through its wholly owned subsidiary Alivira Animal Health, has signed a binding agreement to acquire a 100% stake in BioForLife Italia (BFL) for approximately ₹188 crore. Expected to close in Q2 FY27, the acquisition marks Viyash’s strategic entry into Italy, one of Europe’s largest animal health markets. 

• Based in Milan, BioForLife specializes in the development, commercialization, and distribution of pet care products, with established positions in nutritional supplements, pharmaceuticals, and rapid diagnostic tests. The company is also expanding into high-growth areas such as dermatology and ophthalmology and reaches more than 80% of veterinary clinics in Italy through its established sales network. 

• The acquisition provides Alivira with a platform to launch companion animal products in Italy while expanding BioForLife’s portfolio across Alivira’s markets in Europe, the Middle East, Asia, and Latin America. It also adds BioForLife’s leadership team and strengthens Alivira’s international animal health expansion strategy. 

Implications: 

The all-cash ₹188 crore acquisition gives Alivira immediate access to BioForLife’s established Italian pet-care business in nutraceuticals, pharmaceuticals, and rapid diagnostics, while creating opportunities to launch Alivira’s pipeline products in Italy and expand BioForLife’s brands across Europe, the Middle East, Asia, and Latin America. 

Source: NSE